about
Aurora kinases as prognostic biomarkers in ovarian carcinoma.Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma.Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancerSEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysisPhase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumoursUrine telomerase for diagnosis and surveillance of bladder cancer.Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors.Molecular characterization of ovarian cancer by gene-expression profiling.Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives.The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.Zebrafish: a new companion for translational research in oncology.New Horizons for Precision Medicine in Biliary Tract Cancers.Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas.Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology.MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.Telotristat ethyl: a new option for the management of carcinoid syndrome.Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy.Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.Tumoural Expression of Connective Tissue Growth Factor (CTGF) Impacts on Survival in Patients Diagnosed with Hepatocellular Carcinoma (HCC).Zebrafish in oncology.A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition.Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing.PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium.Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy.Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumoursThe HER3 pathway as a potential target for inhibition in patients with biliary tract cancersRAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation
P50
Q27851462-B5408AA9-758D-4182-A764-8A0EEF773B60Q33392201-A197DBF9-5B10-4987-BD5B-C7F849D483FDQ33394751-E668310E-4A03-4BC4-8E37-C5D49D86B2CCQ33396235-96F5D3EF-E132-4254-8829-8362F0DA7BC3Q33410627-8DD04C30-45BC-40AF-8CA8-896F6FEDE98CQ33436462-D15BF1E9-7A39-4DF1-9B90-CE1C8F1D22B1Q34051972-7FCF3ED7-CA97-42CD-A5BD-E95D23681B1FQ34553547-A5558508-503C-4F61-BF53-689027F48D98Q35681825-DADCB35F-C81B-4BC5-91B6-5052BB79F404Q35998482-0ABA6B82-E327-42F2-8396-C8FACCD62DF7Q36134957-B7F78C4B-9B32-4006-8973-D49B4A92D96BQ37222606-DF26274A-0268-4112-A6A0-145E0C70F3D5Q37314269-9F0EE26C-EB54-4B2F-A94A-F3AD9F0AF293Q37741508-DEEA93E1-7F1E-4CA4-832D-7BE9104B8D4DQ37959323-AB8C6EB1-E246-4FAB-B371-99070FFB7C00Q38077870-8A145878-0EE6-40A4-9F32-E37F2607BE72Q38091161-144CA8A5-64E6-467F-9119-6ACD9BD3345BQ38099268-45C3FF1D-F5C2-4CAF-8A0F-18F7308371C4Q38221411-2D795F63-B2CE-4B3C-8E3B-E66CDD5C2751Q38312265-9ACCD54D-08E9-4B44-AB22-9B6E9F837D12Q38619219-ABDCCD5B-D5C5-4392-B518-FE60D68019CFQ38726113-AC5F8FF8-511B-41A3-9042-6D4912863D75Q38764884-8994CCDB-768D-4A54-B62A-E9EAC2494470Q38884212-E31B0234-5EB7-4906-BE06-938556C976E2Q38898999-0C6C4DD7-BD69-4702-88DA-E7DCD5A2BDACQ39000212-EF15C184-97E3-411D-B497-5E16BA14F9E0Q39997738-6831C210-8721-47BF-83EC-0073FDA14B45Q40794876-F20553B8-CA77-43A2-A0CF-7A7EA35A7CEFQ41109912-4DA76F4A-7400-4305-8CB0-853ECDC7A96EQ42430934-A75099E8-69CC-4E83-8673-D84069EBD3A5Q44556310-FF3910E0-0735-4F43-8A01-D7A25F0A9D42Q46113233-7BC448CC-5DB8-4BFE-9E68-F8E90E0305A0Q52353746-0649F8AD-E7C5-4F45-B06B-48629CE2F573Q52723008-F36A4E5F-4161-45CD-9BCA-72A3DC00DB51Q54646316-1231E562-BA08-4A39-AA68-3DA3EB5CB2FCQ54655477-902EB5FD-CF7C-47A3-9898-6BE1627B1E9DQ55417277-424037CC-6278-4CDD-A65B-F38A7A7A9DFFQ57191163-E2EFC828-BB3D-4F09-8457-B3A8E0B255D0Q58601441-8815737E-5967-43BB-A3C9-FD8393D33B53Q58763445-9BEB2625-F86B-46F2-91D6-DA5F7A9787DD
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-5641-9105
@en
name
Jorge Barriuso
@ast
Jorge Barriuso
@en
Jorge Barriuso
@es
Jorge Barriuso
@nl
type
label
Jorge Barriuso
@ast
Jorge Barriuso
@en
Jorge Barriuso
@es
Jorge Barriuso
@nl
prefLabel
Jorge Barriuso
@ast
Jorge Barriuso
@en
Jorge Barriuso
@es
Jorge Barriuso
@nl
P106
P1153
8912143100
P21
P31
P496
0000-0002-5641-9105